Truist lowered the firm’s price target on Ultragenyx (RARE) to $100 from $140 and keeps a Buy rating on the shares. The company’s Q1 results were in-line and the management reiterated its FY25 revenue guidance, though the firm’s price target is cut on tampered outlook for gene therapy programs, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Promising Pipeline and Consistent Demand
- Ultragenyx Pharmaceutical: Undervalued Stock with Promising Pipeline and Strategic Entry Point
- Investors will be rewarded for buying Ultragenyx at $35, says Citi
- Buy Recommendation for Ultragenyx Pharmaceutical Driven by Strong Commercial Execution and Promising Pipeline
- Ultragenyx Pharmaceutical: Promising Developments and Strategic Progress Drive Buy Rating